Introduction
============

Schizophrenia is a debilitating psychiatric illness with a lifetime prevalence of around 0.4%^[@bib1]^ and a heritability estimated to be between 80 and 85%.^[@bib2],\ [@bib3]^ One schizophrenia susceptibility gene that has attracted much attention is *Disrupted-in-Schizophrenia*-*1* (*DISC1*). *DISC1* is one of the three genes (with *DISC2* and *TSNAX*) lying at the site of a balanced t(1;11)(q42.1;q14.3) translocation, which has a strong association (logarithm of the odds ratio=7.1) with schizophrenia and other mental illness in a large Scottish pedigree.^[@bib4],\ [@bib5]^

Further evidence that *DISC1* genetic variants predispose to schizophrenia in particular comes from four sources. First, the expression of the protein product DISC1 is reduced in the Scottish pedigree in which the translocation segregates. Second, DISC1 interacts physically with PDE4B. Another Scottish family with schizophrenia has a translocation that reduces the expression of PDE4B.^[@bib6]^ Third, association between schizophrenia and variants at the *DISC1* locus has been reported.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ Fourth, sequencing part of the *DISC1* gene in 288 cases identified six rare coding variants not found in 10 000 controls.^[@bib21]^

These findings, along with evidence of DISC1\'s involvement in other mental illnesses including bipolar disorder,^[@bib19]^ depression^[@bib11]^ and autism,^[@bib22]^ have spurred research into understanding what DISC1 does in the brain. Studies of DISC1\'s interactome have revealed that it is involved in synaptic development pathways^[@bib23]^ and interacts with proteins important for neural development such as NDEL1.^[@bib24],\ [@bib25],\ [@bib26]^ These results seem promising for DISC1\'s role in schizophrenia in light of the common hypothesis that the origin of the condition is neurodevelopmental.

However, there has been no comprehensive meta-analysis of schizophrenia association study findings for *DISC1*, despite the fact that the association evidence is not totally consistent. Association has been reported over almost the entire gene ([Figure 1](#fig1){ref-type="fig"}; refs.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^), but the largest study to date failed to detect any association,^[@bib27]^ and genome-wide association studies (GWAS) have not found a clear signal at *DISC1*.

Meta-analysis of *DISC1* findings is difficult to carry out because the gene is large (414 kb) and includes many variants (2603 single-nucleotide polymorphisms (SNPs) in single-nucleotide polymorphism database (dbSNP) 131). There is no consensus about which markers have the strongest association, no markers are tested in all studies and most are tested in only a small number of studies. Therefore, we decided to try to combine data from studies that use different markers by imputation. This method estimates results from a marker that has not been genotyped by exploiting linkage disequilibrium with markers that have been genotyped.

Until recently, there was insufficient sequence information at the *DISC1* locus to make imputation feasible; however, release of data from phase 3 of the International HapMap project^[@bib28]^ and from the first 1000 Genomes pilot^[@bib29]^ provide the most comprehensive catalog of common human genetic variation available today, including rare variants. We set out to use these publicly available data to impute genotypes in DISC1 association studies and to combine results from all available sources, including both GWAS and candidate gene studies, thus overcoming the problems described above.

Methods
=======

Selection of studies for inclusion
----------------------------------

We identified candidate gene studies and GWAS for schizophrenia or schizoaffective disorder in unrelated case--control samples drawn from populations of predominantly European ancestry with at least 100 cases and controls. Studies reporting data on both male and female cases and controls were included. We did not include studies where data from multiple individuals was pooled and analyzed together. We excluded studies where the samples overlapped significantly with another identified study.

Systematic literature search
----------------------------

We considered all studies listed for DISC1 on the SZGene database.^[@bib30]^ We also searched PubMed with the search terms 'DISC1\' AND 'Schizophrenia\' AND 'Association\' and also for the terms 'Schizophrenia\' AND 'GWAS\'. Once these had been collected, their bibliographies were then searched for additional references. The abstracts of studies thus identified were examined with respect to the inclusion criteria above. Studies failing to meet the criteria were discarded, and the full text of remaining studies was examined to determine whether or not they should be included.

Data extraction
---------------

For each study, the following data were extracted: (1) author(s) and year of publication; (2) sample size; and (3) data (individual genotypes, genotype counts or minor allele frequencies (MAFs) in order of preference). Where the required data were not available in the published study or from web-based supplementary information, we contacted the authors of the paper by email to request access to the data. For GWAS, we requested data for the region extending 100 kb upstream of *DISC1* and downstream of *TSNAX* (Chr1: 231 572 000--232 277 000 in the hg19 genome assembly), which covers all reported associations.

Quality control
---------------

In addition to any quality control performed by the authors of the studies, we excluded any SNPs that failed the following tests: (1) MAF in cases or controls \<0.01. (2) Where alleles were given in the study data, we checked them against dbSNP alleles^[@bib31]^ and excluded the SNP if the reported alleles differed from the dbSNP alleles and could not be explained by a strand flip. We also excluded the SNP if no alleles were specified in the study data and the MAF was \>0.45; otherwise, we coded the SNP by the minor allele. (3) For studies where we had genotype counts available, we excluded SNPs that had a Hardy--Weinberg equilibrium test *P*-value of \<0.001.

Imputation
----------

One of the problems encountered in previous attempts at meta-analysis is the lack of overlap between studies in terms of tested SNPs. We addressed this problem by imputing genotypes for studies where we had full genotype data. Imputation was carried out using IMPUTE v.2,^[@bib32],\ [@bib33]^ with reference panels of CEU haplotypes from HapMap 3 and the 1000 Genomes pilot 1. The CEU haplotypes are taken from samples from the Centre d\'Etude du Polymorphisme Humain collected from individuals living in Utah, USA, with ancestry from northern and western Europe. The haplotype data were obtained from the IMPUTE website (<http://mathgen.stats.ox.ac.uk/impute/impute.html>). For studies where we did not have full genotype data (we had genotype counts or MAFs), we imputed MAFs using the linear predictor implemented in the BLIMP package^[@bib34]^ and the CEU haplotypes from 1000 Genomes pilot 1. We attempted to impute for all studies that genotyped at more than 10 SNPs.

Size and power calculations
---------------------------

To calculate the size and power of the meta-analysis, we simulated case--control data from haplotypes drawn from the 1000 Genomes pilot 1. To calculate the *P*-value required to obtain a given significance level, we sampled data from the 1000 Genomes haplotypes, with the same characteristics as the studies in the sample (numbers of cases, controls and testing the same SNPs), calculated effect sizes and *P*-values as described below and obtained the empirical significance levels for each SNP. We repeated the simulation and determined the required nominal point-wise significance level required to achieve a gene-wide significance level of 0.05.

To calculate the power of the meta-analysis, we again sampled from the 1000 Genomes data with the same characteristics as the meta-analysis samples, but in each simulation, we chose a SNP at random and weighted the sampling probabilities in cases to ensure that the chosen SNP had a specified odds ratio (OR) in cases relative to controls. We performed the analysis as described below and recorded whether the significance level determined above was reached by any SNP. The proportion of tests with any SNP reaching significance gave us an estimate of the power of the meta-analysis for a given effect size. For size calculations, we performed 10 000 simulations, and for power calculations, we performed 1000 per data point.

Statistical analysis
--------------------

Log-ORs (equivalent to logistic regression coefficients) and their standard deviations were calculated for each SNP in each study and then combined across studies using fixed and random effects models.^[@bib35]^ We tested whether any of the pooled *P*-values were more significant than the thresholds calculated above. We also tested whether the distribution of *P*-values differed significantly from that expected under the null hypothesis. For each SNP, we investigated whether there was any evidence for heterogeneity using the *I*^2^ statistic.^[@bib36]^

For the imputed genotypes, we calculated the test statistics using SNPTEST,^[@bib32]^ which takes into account the genotype uncertainty generated by the imputation. For imputed allele frequencies, we calculated the proportion of the genotypic variance explained by the imputation, and filtered out any SNP where this was below 80%. We then calculated test statistics as for the original data. These were then combined with the test statistics from genotyped SNPs as above. We considered separately: (1) the genotyped data; (2) the genotyped data plus the imputed data, but considered only loci that were genotyped in at least one study; and (3) the genotyped data plus all the imputed data. We removed each study from the meta-analysis in turn to determine whether any single study had a disproportionate effect on the analysis. We also calculated Wakefield approximate Bayes factors^[@bib37]^ from estimates of the standardized effect sizes and their variances, assuming a prior for the effect size that was normally distributed with mean 0 and variance 0.015. This prior is equivalent to the belief that for each SNP, there is a 95% probability that its OR lies between 0.79 and 1.28.

Results
=======

We obtained data for 11 candidate gene studies and four GWAS containing a total of 11 626 cases and 15 237 controls ([Table 1](#tbl1){ref-type="table"}). We could not obtain data from one case--control study and one GWAS matching our criteria because there was no response from the authors. Three studies were excluded because they overlapped substantially with other studies ([Table 2](#tbl2){ref-type="table"}). The total number of separate SNPs genotyped in any study was 401.

Imputation dramatically increased the number of studies testing each SNP. Before imputation, 100 SNPs were tested in a single study only. After imputation, there were only 13 such SNPs. The mean number of studies testing each SNP increased from 2.6 to 4.3, if only sites genotyped in a single study were considered, and to 3.4 if all imputed sites were used. Ultimately, we obtained data on a total of 1241 separate SNPs. Many of the SNPs in the full imputed data set were tested in only two studies and were heavily dependent on the International Schizophrenia Consortium data.^[@bib38]^

For testing the 401 genotyped loci, we used a point-wise significance level of 1.92 × 10^−4^ corresponding to a gene-wide significance level of 0.05. We generated this threshold by simulation, using the exact SNPs and sample sizes available in the included studies. It is equivalent to a multiple testing correction for 260 (95% confidence interval 250--269) independent tests. For the 1241 SNPs in the imputed data, the correction is equivalent to 444 independent tests (95% confidence interval 424--467). With these cutoffs, we estimated that for common variants (MAF \>5%), the power to detect a true association at OR=1.5, with the imputed data restricted to genotyped loci was 99%. For OR=1.1 the power was 51%.

For rare variants, power is much lower. For variants with MAF between 1 and 5%, the corresponding figures are 92 and 6%. For variants with MAF below 1%, which we did not try to test, the power is very low, even for high ORs. These figures are the power to detect an association at any locus given the OR at the causal locus, which is not necessarily the one detected. [Figure 2](#fig2){ref-type="fig"} shows power as a function of MAF for different ORs at the causal allele.

Using these significance thresholds, we detected no significant association with any tested SNP ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). The most associated SNP was rs1765805, 160 kb upstream of *DISC1* (*P*=6 × 10^−4^, genotyped in 1860 cases and 2389 controls), but this was heavily dependent on a single study^[@bib38]^ and not supported by nearby SNPs. The next highest associations were found in the regions of rs1331046 (*P*=1.4 × 10^−3^, imputed in 3610 cases and 3938 controls), downstream of the gene, and rs17817356 (*P*=7 × 10^−3^, genotyped in 4405 cases and 7427 controls, imputed in 2291 cases and 2293 controls), between exons 6 and 7, and about 30 kb upstream from DISC2. Like rs1765805, the association at rs1331046 was driven by the ISC data, but the association at rs17817356 was supported by the ISC and other data sets as well. In the random effects analysis, the associations at rs1765805 and rs17817356 remained at the same significance level, but the association at rs1331046 was substantially reduced (*P*\>0.03).

Excluding the ISC study significantly altered our results, and was the only study whose omission did so. As noted above, the associations at rs1765085 and rs1331046 were supported only by the ISC. However, this may be because few other studies tested these SNPs. Both SNPs are outside the gene, in a region where we had lower coverage, as most candidate gene studies have concentrated on SNPs inside the gene.

To assess heterogeneity, we calculated the *I*^2^ statistic for all SNPs. This was zero for the majority (70%) of loci and distributed between 0 and 80% for the rest. Tests of heterogeneity are generally underpowered when, as here, there are few studies,^[@bib39],\ [@bib40]^ so we cannot make conclusive statements about the presence or absence of heterogeneity. However, given that most genetic associations display between-study heterogeneity^[@bib41]^ and that fixed and random effects models give the same results when there is no heterogeneity, it seems prudent to use the more conservative random effects model to estimate effect size or to prioritize markers for further analysis.

Using the effects estimated by the random effects model, the approximate Bayes factors reveal a similar pattern to the *P*-values ([Figure 5](#fig5){ref-type="fig"}), and indicate that the region around rs17817356 has the most evidence in favor of association and that there is no consistent evidence for association elsewhere in the gene.

There are three commonly tested non-synonymous SNPs in the gene, rs3738401, rs821616 and rs6675281. The variants rs821616 and rs6675281 have been reported to have functional effects, affecting centrosomal PCM1 localization,^[@bib42],\ [@bib43]^ expression of splice variants,^[@bib44]^ hippocampal function^[@bib45]^ and interaction with NDEL1, which is important for neurite outgrowth.^[@bib46]^ However, we detected no significant associations at any of these SNPs (*P*=0.11, 0.51 and 0.93 in the raw data and 0.49, 0.60 and 0.28 in the imputed).

Given the potential contribution of rare variants in *DISC1* to schizophrenia risk, we searched additional sources of data to identify further functional variants not represented in dbSNP. In the 1000 Genomes pilot data, we found one additional non-synonymous coding SNP. We also looked in the results from a recent exome sequencing study of 200 Danish individuals^[@bib47]^ and identified five novel non-synonymous SNPs. Of these six variants, two had been discovered in cases and controls by Song *et al.*^[@bib21]^ and four were novel ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

We have carried out a comprehensive analysis of candidate schizophrenia susceptibility variants in the *DISC1* gene. We found no significant association with any variant. We calculated approximate Bayes factors for each SNP to identify the regions where there was most evidence of association and found that the best evidence of association was in a region between exons 6 and 7. Our meta-analysis had to deal with the problem that of 401 variants reported in the literature, 120 markers were tested in a single study and a further 110 in just two studies. The lack of overlap in the markers tested in different studies poses a challenge to meta-analysis that we overcame by imputing genotypes. By combining results from genome-wide association and candidate gene studies together with LD data from the HapMap and 1000 Genomes projects, we were able to test the involvement of 1241 SNPs in a combined sample of 11 626 cases and 15 237 controls.

Our results raise four questions. First, what range of effects have we tested? Second, to what extent have we excluded the involvement of common variants throughout the gene? Third, can we draw any conclusions about the role of rare variants at the *DISC1* locus? Finally, why have we been unable to replicate the many previously reported associations?

Power calculations help to answer the first question ([Figure 2](#fig2){ref-type="fig"}). Power depends critically on the sample size, which is not straightforward to estimate. Although the total number of cases and controls in our sample was 11 626 and 15 237, not every SNP was tested in every individual. In the raw data, the mean numbers of cases and controls testing any single SNP were 2781 and 3782. We cannot directly calculate the sample sizes for the imputed data as we used imputed genotype probabilities in our tests, but comparison of the variance of test statistics suggests that the mean improvement was equivalent to increasing the sample size by 49% to a mean of 4144 cases and 5653 controls. These figures are heavily skewed in the sense that some variants have much larger sample sizes. Imputation also allowed us to test variants that had not been genotyped in any study.

Our power calculations are only approximate as we sampled from a fairly limited set of haplotypes. However, they can give us an indication of what effects we have tested. For variants with MAF \>5%, we had 99% power to detect an effect with OR=1.5 and 51% power to detect an effect with OR=1.1. However, it is possible that effects will be too small to detect, even for high-frequency variants. Robust association for common variants with OR of \<1.1 have been reported in a study of height^[@bib48]^ and it is not inconceivable that similarly small effects operate in schizophrenia.^[@bib49]^ It has been argued that such variants can explain a significant proportion of the heritability for common diseases and traits.^[@bib38],\ [@bib49],\ [@bib50]^

Results from the HapMap and 1000 Genomes projects provide an answer to the second question. Genotyped SNPs included 32% of all SNPs with MAF \>5% in the 1000 Genomes, and imputed SNPs included 89%. For SNPs with MAF between 1 and 5%, the corresponding figures are 10 and 41%. For genotyped loci, 95% of the gene is within 5.0 kb of a tested SNP, 50% is within 1.4 kb and the maximum distance without a tested SNP is 13.7 kb. For the imputed data, the figures are 2.6, 0.6 and 7.2 kb. These small regions make it unlikely that any common SNP could exist that we have not, at least indirectly, tested.

Third, the effects may arise from alleles too rare to be tested here. It is not surprising that common variants do not have a large effect on susceptibility to such a debilitating disease, but we might expect rare variants to have larger effects. Although we tested variants down to an MAF of 1%, we had very low power at this level, and we could not even test all the known variants of this frequency. Further stages of the 1000 Genomes project will allow most variants at this frequency to be tested. On the other hand, association between DISC1 and the disease might derive from extremely rare, essentially private, mutations of large effect.^[@bib51],\ [@bib52]^ One study reported the identification of coding mutations in schizophrenia cases that were not detected in 10 000 control subjects.^[@bib21]^ However, this study did not search in healthy controls for rare variants that were not found in cases. In two studies sampling 260 individuals in total, we found four novel non-synonymous mutations, and rediscovered two that had been identified in the previous study. This suggests that coding mutations in DISC1 may be more common in healthy individuals than previously assumed. However, it should also be noted that control subjects were not actively screened for the absence of schizophrenia, a family history of schizophrenia or related mental illnesses.

Finally, many previous studies have reported association. There are a number of reasons why we might have failed to replicate these results; publication bias, winner\'s curse, allelic heterogeneity and population, sex or subgroup-specific heterogeneity. We have not attempted to investigate these here, but it is worth noting that the presence of heterogeneity of effects would particularly tend to confound large GWAS and meta-analyses such as this one.

Our meta-analysis does not address the question of *DISC1*\'s involvement in other mental illness, such as bipolar disorder, major depressive disorder or autism spectrum disorder, nor does it answer all the questions with regard to the association of *DISC1* with schizophrenia. Although we found no significant association with common variants, many studies have reported sex-specific and interaction effects,^[@bib9],\ [@bib11],\ [@bib12],\ [@bib18],\ [@bib19]^ which we did not test. Consideration of the power required to detect such effects suggests that if they do exist, significantly larger studies will be required to detect them convincingly. For example, if we were to test all pairwise SNP--SNP interactions for all imputed SNPs in this study, we would be increasing the multiple testing factor by around 100 000. We would also be reducing the sample size for each test, particularly for combinations of rare variants, making it difficult, if not impossible, to reach statistical significance. Hypothesis-driven tests derived from functional studies and model systems may prove more productive than data mining in this case.

Whatever the true effect of the factors described above, it seems likely that we will need to consider new study designs and new statistical techniques to further investigate the effect of *DISC1* variation on schizophrenia and other psychiatric illnesses.
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![Reported *Disrupted-in-Schizophrenia-1* (*DISC1*) associations including both family and association studies from populations of all ethnicities and indicating regions reported as being significantly associated with schizophrenia.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ These includes family-based linkage studies and studies in non-European populations, which were not included in this study. The numbers to the right of the graph indicate numbers of cases/controls in the study.](mp201141f1){#fig1}

![Estimated power as a function of minor allele frequency at the causal allele, showing results for different odds ratios. The power was simulated using variants and haplotypes from the 1000 Genomes data and the curves have been fitted as smooth splines of degree 6.](mp201141f2){#fig2}

![Pooled *P*-values for association. Each point represents a single-nucleotide polymorphism (SNP). The horizontal axis indicates chromosomal position, and the vertical axis indicates negative log~10~ of the fixed-effect pooled *P*-value for that SNP. The black points show the imputed SNPs and the gray points show the subset of the imputed SNPs, which were genotyped in at least one study. The horizontal dashed lines show the corrected significance level, which is equivalent to a 5% gene-wide significance level for each data set.](mp201141f3){#fig3}

![Quantile--quantile (QQ) plot of *P*-values. QQ plot of the *P*-values shown in [Figure 2](#fig2){ref-type="fig"}. The solid line shows the expected values under the null hypothesis of no association and the dashed lines show the upper and lower 95% quantiles.](mp201141f4){#fig4}

![Wakefield approximate Bayes factors for each single-nucleotide polymorphism (SNP). Calculated from the random effects pooled *P*-values and *Z*-scores assuming a normal prior on the log-OR, with mean 0 and variance of 0.015. A Bayes factor \>0 is evidence for association, whereas a Bayes factor \<0 is evidence against.](mp201141f5){#fig5}

###### Details of studies analyzed

                                     SNPs tested                     
  --------------------------------- ------------- ----- ----- ------ ------
  Devon *et al.*^CM[@bib53]^            2001      3     0     656    344
  Hodgkinson *et al.*^CF[@bib14]^       2004      38    62    242    213
  Wood *et al.*^CF[@bib54]^             2007      74    328   451    291
  Song *et al.*^CS[@bib21]^             2008      3     0     288    288
  Saetre *et al.*^CS[@bib17]^           2008      15    52    837    1473
  Sanders *et al.*^CF[@bib27]^          2008      114   521   1870   2002
  O\'Donovan *et al.*^GM[@bib55]^       2008      115   180   478    2937
  Betcheva *et al.*^CM[@bib56]^         2009      14    46    255    556
  Hennah *et al.*^CS[@bib12]^           2009      62    136   1263   1275
  Rastogi *et al.*^CS[@bib16]^          2009      9     0     210    210
  Schumacher *et al.*^CM[@bib18]^       2009      108   210   782    839
  Need *et al.*^GS[@bib57]^             2009      72    138   673    871
  ISC *et al.*^GF[@bib38]^              2009      224   832   3322   3587
  Athanasiu *et al.*^GF[@bib58]^        2010      250   955   298    351

Abbreviations: C, candidate gene(s); F, full genotypes; G, genome-wide association studies; Gen, genotyped; Imp, imputed; M, minor allele frequencies; S, summary genotypes; SNP, single-nucleotide polymorphism.

###### Studies that met our inclusion criteria, but which were not included

  *Study*                          *Year*  *Reason for exclusion*
  ------------------------------- -------- ---------------------------------------------------------
  Thomson *et al.*^[@bib19]^        2005   Samples reported in Hennah *et al.*^[@bib12]^
  Zhang *et al.*^[@bib20]^          2006   Samples partially reported in Hennah *et al.*^[@bib12]^
  Lencz *et al.*^[@bib59]^          2007   Samples reported in Hodgkinson *et al.*^[@bib14]^
  Nicodemus *et al.*^[@bib60]^      2007   No response from author[a](#t2-fn2){ref-type="fn"}
  Stefansson *et al.*^[@bib61]^     2009   No response from author[b](#t2-fn3){ref-type="fn"}

'No response from author\' refers to email response to the corresponding author, specifically.

We received an initial response, but no response to two further emails.

No response after three initial emails.

###### Non-synonymous SNPs not found in dbSNP identified in 260 individuals

  *Position (hg18)*    *NT substitution*   *AA substitution*   *Source*   *Song et al.?*
  ------------------- ------------------- ------------------- ---------- ----------------
  229 896 375                 C/T                A83V             47           Yes
  229 896 606                 G/T                W160L            47            No
  229 896 987                 C/T                P287L            47            No
  229 897 063                 T/G                C312W            47            No
  229 969 594                 T/C                I452F            47            No
  230 969 594                 A/T                E751Q            29           Yes

Abbreviation: AA, amino acid; dbSNP, single-nucleotide polymorphism database; NT, nucleotide. Two have been found in a previous study and four are novel.
